



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Bae Abertawe
Swansea Bay University
Health Board

Cadeirydd/Chair: **Emma Woollett**
Prif Weithredwr/Chief Executive: **Mark Hackett**

gofalu am ein gilydd, cydweithio, gwella bob amser
caring for each other, working together, always improving

Rydym yn croesawu gohebiaeth yn y Gymraeg ac yn y Saesneg. We welcome correspondence in Welsh or English.

Dyddiad/Date: 20th May 2021
Ein Cyf / Our Ref: 21-D-028

☎ 01639 648363

✉ FOIA.Requests@wales.nhs.uk

[REDACTED]

Corporate Services
Headquarters
1 Talbot Gateway
Baglan
Port Talbot, SA12 7BR

[REDACTED]

I refer to your Freedom of Information Act Request acknowledged by ourselves on 26th April 2021. Your request sought information relating to Oncology treatments.

Please note that we have provided the information for the period 01.10.20 to 31.03.21.

1. How many patients were treated (for any condition) in the past 6 months with:

- **Abiraterone** - 33
- **Apalutamide** - <4*
- **Cabazitaxel** - 13
- **Darolutamide** - <5*
- **Docetaxel** - 39 (single agent)
- **Enzalutamide** - 90
- **Ruxolitinib** - 7

2. Please provide the total number of patients treated in the last 6 months for

Please note that we have provided numbers for patients newly diagnosed that have received their first definitive treatment.

- **Myelofibrosis (ICD10 code D47.4)** - 0
- **Myelofibrosis (ICD10 code D47.4) patients over the age 65** - <5*
- **Prostate cancer** - 152



Pencadlys BIP Bae Abertawe, Un Porthfa Talbot, Port Talbot, SA12 7BR / Swansea Bay UHB Headquarters, One Talbot Gateway, Port Talbot, SA12 7BR

Bwrdd Iechyd Prifysgol Bae Abertawe yw enw gweithredu Bwrdd Iechyd Lleol Prifysgol Bae Abertawe
Swansea Bay University Health Board is the operational name of Swansea Bay University Local Health Board

- **Metastatic prostate cancer** – 21

3. How many myelofibrosis (ICD10 code D47.4) patients has your Health Board diagnosed in the past 3 years?

<5*

- **Of these patients, how many were treated in the past 6 months with Hydroxyurea?**

0

- **Of these patients, how many have received no active treatment in the past 6 months?**

<5*

4. How many metastatic prostate cancer patients were treated in the past 6 months with:

- **Abiraterone** - 31
- **Apalutamide** - <5*
- **Cabazitaxel** - 13
- **Darolutamide** - <5*
- **Docetaxel** - 20
- **Enzalutamide** - 89

* Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

I hope this information is helpful. If you require anything further please contact us at FOIA.Requests@wales.nhs.uk.

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via FOIA.Requests@wales.nhs.uk.

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.

Yours sincerely





On behalf of

Pam Wenger

Director of Corporate Governance

